| Year | 2023 | 2022 |
|---|---|---|
| Total Revenue | 18.16B | 19.45B |
| Cost of Revenue | 14.25B | 11.7B |
| Gross Profit | 3.91B | 7.75B |
| Operating Expenses | 7.01B | 4.96B |
| Research and Development | 83.7M | 139.61M |
| Selling, General & Administrative Expenses | 803.59M | 654.3M |
| Selling & Marketing Expenses | 679.71M | 588.14M |
| General & Administrative Expenses | 123.87M | 66.17M |
| Other Expenses | 49M | 23.2M |
| Operating Income | 3.13B | 2.82B |
| Total Other Income/Expenses Net | -123.2M | -187.34M |
| Income Before Tax | 3B | 2.61B |
| Income Tax | 835.9M | 672.9M |
| Net Income | 2.17B | 1.93B |
| Basic EPS | 23.93 | 21.35 |
| EPS Diluted | 23.93 | 21.35 |
| Basic Average Shares | 90.64M | 90.63M |
| Diluted Average Shares | 90.63M | 90.63M |
| EBITDA | 3.91B | 3.44B |
Aarti Pharmalabs Limited
AARTIPHARM.NS
NSE
679.4INR55 (-0.25%)
AARTIPHARM.NS Financial Statements
Retained Earning Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Retained Earnings (Previous Year) | 8.89B | 7.17B |
| Net Income | 2.17B | 1.93B |
| Stock Repurchases | 0 | 0 |
| Dividend Paid | -181.25M | -181.25M |
| Retained Earnings | 10.86B | 8.89B |
| Other Distributions | 1.78B | 1.54B |
PPE Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Gross PPE | 11.05B | 9.86B |
| Annual Depreciation | 732.35M | 625.43M |
| Capital Expenditure | -1.99B | -1.2B |
| Net PPE | 12.31B | 10.43B |
Intangible and Goodwill Schedule
| Year | 2023 | 2022 |
|---|---|---|
| Acquisitions and Adjustments | 6K | -6K |
| Goodwill (Previous Year) | 17.8M | 17.81M |
| Goodwill | 17.81M | 17.8M |